These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 25061302)

  • 1. Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.
    Schoedel KA; Morrow SA; Sellers EM
    Neuropsychiatr Dis Treat; 2014; 10():1161-74. PubMed ID: 25061302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
    Patatanian E; Casselman J
    Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.
    Pioro EP
    Neurol Ther; 2014 Jun; 3(1):15-28. PubMed ID: 26000221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study.
    Hammond FM; Sauve W; Ledon F; Davis C; Formella AE
    PM R; 2018 Oct; 10(10):993-1003. PubMed ID: 29477412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
    Hammond FM; Alexander DN; Cutler AJ; D'Amico S; Doody RS; Sauve W; Zorowitz RD; Davis CS; Shin P; Ledon F; Yonan C; Formella AE; Siffert J
    BMC Neurol; 2016 Jun; 16():89. PubMed ID: 27276999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
    Pattee GL; Wymer JP; Lomen-Hoerth C; Appel SH; Formella AE; Pope LE
    Curr Med Res Opin; 2014 Nov; 30(11):2255-65. PubMed ID: 25062507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dextromethorphan/quinidine sulfate for pseudobulbar affect.
    Rosen H
    Drugs Today (Barc); 2008 Sep; 44(9):661-8. PubMed ID: 19137121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain.
    Olney N; Rosen H
    IDrugs; 2010 Apr; 13(4):254-65. PubMed ID: 20373255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
    Doody RS; D'Amico S; Cutler AJ; Davis CS; Shin P; Ledon F; Yonan C; Siffert J
    CNS Spectr; 2016 Dec; 21(6):450-459. PubMed ID: 26471212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
    Brooks BR; Thisted RA; Appel SH; Bradley WG; Olney RK; Berg JE; Pope LE; Smith RA;
    Neurology; 2004 Oct; 63(8):1364-70. PubMed ID: 15505150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial.
    Zorowitz RD; Alexander DN; Formella AE; Ledon F; Davis C; Siffert J
    PM R; 2018 Jun; ():. PubMed ID: 29964212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.
    Schoedel KA; Pope LE; Sellers EM
    Clin Drug Investig; 2012 Mar; 32(3):157-69. PubMed ID: 22283559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect.
    Haiman G; Pratt H; Miller A
    J Clin Psychopharmacol; 2009 Oct; 29(5):444-52. PubMed ID: 19745644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.
    Yang LP; Deeks ED
    Drugs; 2015 Jan; 75(1):83-90. PubMed ID: 25420446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dextromethorphan/quinidine: in pseudobulbar affect.
    Garnock-Jones KP
    CNS Drugs; 2011 May; 25(5):435-45. PubMed ID: 21476614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.
    Panitch HS; Thisted RA; Smith RA; Wynn DR; Wymer JP; Achiron A; Vollmer TL; Mandler RN; Dietrich DW; Fletcher M; Pope LE; Berg JE; Miller A;
    Ann Neurol; 2006 May; 59(5):780-7. PubMed ID: 16634036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use.
    Taylor CP; Traynelis SF; Siffert J; Pope LE; Matsumoto RR
    Pharmacol Ther; 2016 Aug; 164():170-82. PubMed ID: 27139517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect.
    Miller A; Panitch H
    J Neurol Sci; 2007 Aug; 259(1-2):67-73. PubMed ID: 17433820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of pseudobulbar affect (PBA) in a patient with a history of traumatic brain injury, partial brain resection, and brainstem stroke: a case report.
    Young FG; Nguyen D
    J Med Case Rep; 2020 Dec; 14(1):235. PubMed ID: 33272325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis.
    Sancho J; Ferrer S; Burés E; Luis Díaz J; Torrecilla T; Signes-Costa J; Servera E
    Respir Med; 2021 Sep; 186():106536. PubMed ID: 34260979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.